All News

Amy Luckenbaugh, MD, is an assistant professor of Urology at Vanderbilt University Medical Center.

"If the diversity and robust functional potential of the healthy human microbiome is repeatedly assaulted by the average Westernized lifestyle via antibiotic exposure, diet, and other environmental factors, kidney stone prevalence will continue to increase," the authors write.

Findings from the research showed that 68Ga-RM2 PET/MRI had an 85.2% sensitivity rate for diagnosing biochemical recurrence of prostate cancer.

The combination was explored in genomically defined metastatic renal cell carcinoma cohorts.

A response by the FDA is expected by February 2024.

"The Bladder CARE Assay's quantitative nature sets it apart from other tests," said Siamak Daneshmand, MD.

Overall, 177Lu-PNT2002 demonstrated a median radiographic progression-free survival of 9.5 months, compared with 6.0 months among patients who were treated with an ARPI.

The BLA submission is supported by findings from the phase 3 ZIRCON study, which demonstrated high specificity and sensitivity of the agent for PET/CT imaging of ccRCC.

Bogdana Schmidt, MD, MPH, outlines key bladder cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.

Expert advice for physicians seeking new coverage.

The IND clearance will initiate a phase 2 registrational study to investigate the safety and efficacy of NRX-101 in patients with complicated UTIs.

The approval is supported by findings from the phase 3 EV-302 trial, which showed that the combination led to significant improvements in overall survival and progression-free survival compared with chemotherapy.

Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.

“What it brought up is the point that where the field seems to be going is incorporating the PET imaging and the MRI imaging, and maybe PET MRI,” says Michael S. Cookson, MD, MMHC, FACS.

The approval is supported by findings from the phase 3 LITESPARK-005 trial.

All of those enrolled in the study have been implanted for at least 7 months, with the longest implantation at 15 months.

In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.

Novel research to evaluate noninvasive treatments in erectile dysfunction and chronic pelvic pain

All patients had prostates greater than 80 mL and had not responded to prior medication therapy.

Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon Transplant System, a rectal spacer for use in prostate cancer radiation.

The center will offer a comprehensive range of treatments, including prostate artery embolization for men suffering from benign prostatic hyperplasia with very large prostates.

“Physician recipients of peer support reported improved well-being, decreased negative emotions and stigma, and perceived positive cultural changes within their departments,” the authors wrote.

225Ac-PSMA-J591 showed promising efficacy in mCRPC metastatic sites that are commonly resistant to 177Lu-PSMA-617.

The median number of harms criteria reported in RCTs in urology increased from 5.3 in 2012 to 7.2 in 2020.

“We found that these genetic proxies of thiazide diuretics were associated with a 15% lower risk of kidney stones,” says Jefferson Triozzi, MD.

"Our studies consistently demonstrated that data from the Decipher Prostate Genomic Classifier was more reliably predictive of prostate cancer progression and underlying pathology than any other clinical data available, including MRI," says Eric Kim, MD.

Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10% higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the 2023 RSNA Annual Meeting.

Correlation found between the biomarker HSD3B1 and resistance to combined hormone therapy and radiotherapy